Erasca Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ErascaDer Gewinn des Unternehmens wird voraussichtlich um 8.8% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 80.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -74.6% betragen.

Wichtige Informationen

-8.8%

Wachstumsrate der Gewinne

4.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	80.3%
Zukünftige Eigenkapitalrendite	-74.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ERAS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-205	-170	-180	4
12/31/2025	1	-173	-134	-135	6
12/31/2024	N/A	-168	-132	-111	6
9/30/2024	N/A	-159	-132	-110	N/A
6/30/2024	N/A	-158	-134	-111	N/A
3/31/2024	N/A	-127	-109	-108	N/A
12/31/2023	N/A	-125	-123	-101	N/A
9/30/2023	N/A	-231	-125	-103	N/A
6/30/2023	N/A	-236	-127	-103	N/A
3/31/2023	N/A	-240	-132	-104	N/A
12/31/2022	N/A	-243	-120	-103	N/A
9/30/2022	N/A	-138	-121	-99	N/A
6/30/2022	N/A	-149	-125	-99	N/A
3/31/2022	N/A	-141	-112	-90	N/A
12/31/2021	N/A	-123	-98	-80	N/A
9/30/2021	N/A	-154	-103	-70	N/A
6/30/2021	N/A	-119	-81	-54	N/A
3/31/2021	N/A	-96	-81	-43	N/A
12/31/2020	N/A	-102	-71	-33	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ERAS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ERAS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ERAS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ERASDie Einnahmen des Unternehmens (80.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: ERASDie Einnahmen des Unternehmens (80.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ERAS wird voraussichtlich in 3 Jahren unrentabel sein.

Erasca Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 11% to US$6.25

Price target decreased by 7.4% to US$9.00

Price target decreased by 19% to US$11.50

Price target decreased by 9.3% to US$15.57

Price target decreased to US$18.60

Recent updates

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca: New Focus After Restructuring, But Need More Differentiation

Erasca, Inc. Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Independent Director recently bought US$182k worth of stock

Price target decreased by 11% to US$6.25

New major risk - Shareholder dilution

Erasca, Inc. has completed a Follow-on Equity Offering in the amount of $159.999999 million.

New minor risk - Shareholder dilution

Erasca, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Erasca, Inc. announced that it expects to receive $45 million in funding

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Co-Founder recently bought US$1.7m worth of stock

Price target decreased by 7.4% to US$9.00

Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$2.0m worth of stock

New minor risk - Share price stability

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Co-Founder recently bought US$275k worth of stock

New minor risk - Share price stability

Price target decreased by 19% to US$11.50

Erasca, Inc. Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca, Inc. Announces Promising Preliminary Data for ERAS-007 Combinations in Patients with Gastrointestinal Malignancies as Part of Two Poster Presentations That Will Be Presented At the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

Erasca, Inc. Further Strengthens Business Leadership with Two Key Promotions

Independent Director recently bought US$55k worth of stock

Price target decreased by 9.3% to US$15.57

Co-Founder recently bought US$284k worth of stock

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Co-Founder recently bought US$231k worth of stock

Co-Founder recently bought US$200k worth of stock

Price target decreased to US$18.60

Erasca, Inc. Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces Preliminary Data for Eras-007 and Eras-601 in Braf-Driven and Ras/Mapk-Altered Solid Tumors

Erasca adds 10% ahead of R&D Day

Erasca, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Erasca, Inc.(NasdaqGS:ERAS) dropped from Russell 2000 Growth Index

Erasca, Inc. Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

Erasca, Inc. Announces Key Appointments

Erasca Appoints Jean Liu to its Board of Directors

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces FDA Clearance of IND Application for Eras-801 in Glioblastoma Multiforme

Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca, Inc. has completed an IPO in the amount of $300 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken